Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 1, 1999, Pages 67-72

  Des Jarlais, Don C ^a,b   Friedman, Samuel R ^c   Perlis, Theresa ^c   Chapman, Tim F ^c   Sotheran, Jo L ^c   Paone, Denise ^a   Monterroso, Edgar ^c   Neaigus, Alan ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Natl R and D Institutes   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; Epidemiology; HIV; Injecting drug use; New injectors; New York City; Substance abuse

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEMOGRAPHY; DRUG DETOXIFICATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RISK; INJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032932520     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199901010-00010     Document Type: Article

References (26)

1. Mann JM, Tarantola DJM, eds. AIDS in the world II. New York: Oxford University Press, 1996.
2. Metzger DS, Woody G, Marmor M, Gross M. Risk characteristics of injection drug users (IDUs) participating in the vaccine preparedness study (VPS). Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
3. Garfein RS, Vlahov D, Galai N, Doherty M, Nelson KE. Viral infections in short-term drug users: the prevalence of the hepatitis C, hepatitis C, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
4. Doherty MC, Garfein RS, Monterroso E, et al. Younger age of initiating injecting drug use is associated with risky behaviors and HIV infection in short-term injectors. Presented at the XI International Conference on AIDS. Vancouver, British Columbia, Canada, 1996.
5. Friedman S, Des Jarlais D, Neaigus A, et al. AIDS and the new drug injector. Nature 1989;339:333-4.
6. Friedman SR, Friedmann P, Telles P, et al. New Injectors and HIV Risk. In Stimson, GV, Des Jarlais DC, Ball A, eds. Drug injecting and HIV infection: global dimensions and local responses. London: Taylor and Francis, 1998.
7. Neaigus A, Friedman S, Jose B, Goldstein M, Curtis R, Des Jarlais DC. Risk factors for HIV infection among new drug injectors. Presented at the IXth International Conference on AIDS, Berlin, 1993.
8. Nicolosi A, Musicco M, Saracco A, Molinari S, Nicolette Z, Lazzarin A. Incidence and risk factors of HIV seroconversion: a prospective study of seronegative drug users from Milan and Northern Italy, 1987-1989. Epidemiology 1990;1:453-9.
9. Nelson KE, Vlahov D, Solomon L, Cohn S, Munoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch Intern Med 1955;155:1305-11.
10. Friedman SR, Des Jarlais DC, Jose B, Neaigus A, Goldstein M, eds. Seroprevalence, seroconversion, and the history of the HIV epidemic among drug injectors. New York: Raven Press, 1994: 137-50.
11. Katz MH. AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14(Suppl 2):S38-46.
12. Holmberg S. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-54.
13. New York City Department of Health. AIDS surveillance update. New York: Office of AIDS Surveillance, 1997.
14. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Atlanta: Centers for Disease Control and Prevention, 1996.
15. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985;103:755-9.
16. Friedman SR, Des Jarlais DC, Sotheran JL, Garber J, Cohen H, Smith D. AIDS and self-organization among intravenous drug users, Int J Addict 1987;22:201-19.
17. Selwyn P, Feiner C, Cox C, Lipshutz C, Cohen R. Knowledge about AIDS and high-risk behavior among intravenous drug abusers in New York City. AIDS 1987;1:247-54.
18. Des Jarlais DC, Friedman SR, Novick D, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989;261:1008-12.
19. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA 1994;271:121-7.
20. SAS Institute I. SAS/STAT user's guide, vol 6. Cary, NC: SAS Institute, 1993.
21. Casriel C, Des Jarlais DC, Rodriguez R, Friedman SR, Stepherson B, Khuri E. Working with heroin sniffers: clinical issues in preventing drug injection. J Substance Abuse Treat 1990;7:1-10.
22. Neaigus A, Atillasoy A, Friedman SR, et al. Trends in the non-injected use of heroin and factors associated with the transition to injecting. In Inciardi J, Harrison LD, eds. Heroin in the age of crack cocaine. Thousand Oaks, CA: Sage, 1997:131-59.
23. Schoenbaum E, Hartel D, Gourevitch MN. Needle exchange use among a cohort of injecting drug users. AIDS 1996;10:1729-34.
24. Friedman S, Neaigus A, Curtis R, Jose B, Des Jarlais D. Social networks, drug injectors ' lives, and HIV/AIDS. New York: Plenum 1998.
25. Novick DM, Trigg HL, Des Jarlais DC, Friedman SR, Vlahov D, Kreek MJ. Cocaine injection and ethnicity in parenteral drug Users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol 1989;29:181-5.
26. Des Jarlais DC, Casriel C, Friedman SR, Rosenblum A. AIDS and the transition to illicit drug injection: results of a randomized trial prevention program. Br J Addict 1992;87:493-8.